Edition 25, 2013
Point of View

Coagulation Promoters in Focus

Zoom image

Blood coagulation is a complex process – and a specialty of Bayer‘s scientists. 25 years after the recombinant Factor VIII molecule with the brand name Kogenate® was first used for the treatment of patients with hemophilia A, the company‘s specialists like Mouang Gomez (photo, right) and her colleagues shown here in the Bayer HealthCare laboratory in Berkeley, USA, are working to enhance treatment options for hemophilia patients. Bayer researchers are currently investigating a Factor VIII molecule specifically designed to protect hemophiliacs from bleeding while reducing the frequency of injections from two to three times to just once a week.

International Users
This website is checked, operated and updated by BAYER at Leverkusen, Germany. It is intended for international use. However BAYER gives no guarantee that the details presented on this website are correct worldwide, and, in particular, that products and services will be available with the same appearance, in the same sizes or on the same conditions throughout the world. Should you call up this website or download contents, please note that it is your own responsibility to ensure that you act in compliance with local legislation applicable in that place.Products mentioned on this website may come in different packaging, in different package sizes, or with different lettering or markings, depending on the country.
In the USA the business of the Bayer Group is conducted by Bayer Corporation. Customers in the USA are requested to address to this entity.